Jefferies analyst Thomas Wei reiterated a Buy rating but trimmed his price target on Synta Pharma. (NASDAQ: SNTA) from $22 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE